The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine

Clinical Infectious Diseases

Volumn 65, Issue 10, 2017, Pages 1644-1651

  Petrie, Joshua G ^a   Malosh, Ryan E ^a   Cheng, Caroline K ^a   Ohmit, Suzanne E ^a   Martin, Emily T ^a   Johnson, Emileigh ^a   Truscon, Rachel ^a   Eichelberger, Maryna C ^b   Gubareva, Larisa V ^c   Fry, Alicia M ^c   Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

household cohort study; influenza; serologic susceptibility; vaccine effectiveness; vaccine response

Indexed keywords

INFLUENZA VACCINE; VIRUS SIALIDASE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; CHILD; COHORT ANALYSIS; COMMUNITY ACQUIRED INFECTION; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; HOUSEHOLD; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; BLOOD; IMMUNOLOGY; INFLUENZA; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; COHORT STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 85032725974     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix608     Document Type: Review

References (33)

1. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
2. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42.
3. Valenciano M, Ciancio B; I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Euro Surveill 2012; 17:20281.
4. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
5. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
6. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
7. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9.
8. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519-28.
9. Thompson MG, Li DK, Shifflett P, et al. Effectiveness of seasonal trivalent influenza vaccine for preventing influenza virus illness among pregnant women: a population-based case-control study during the 2010-2011 and 2011-2012 influenza seasons. Clin Infect Dis 2014; 58:449-57.
10. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
11. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A 1999; 96:14001-6.
12. Ohmit SE, Petrie JG, Malosh RE, et al. Substantial influenza vaccine effectiveness in households with children during the 2013-2014 influenza season, when 2009 pandemic influenza a(H1N1) virus predominated. J Infect Dis 2016; 213:1229-36.
13. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Available at: http://www. who. int/influenza/vaccines/virus/recommendations/ 201402-recommendation. pdf?ua=1. Accessed 16 November 2016.
14. Appiah GD, Blanton L, D'Mello T, et al.; Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015; 64:583-90.
15. D'Mello T, Brammer L, Blanton L, et al.; Centers for Disease Control and Prevention (CDC). Update: Influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:206-12.
16. Mishin VP, Baranovich T, Garten R, et al. A pyrosequencing-based approach to high-throughput identification of influenza A(H3N2) virus clades harboring antigenic drift variants. J Clin Microbiol 2017; 55:145-54.
17. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza a(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis 2016; 214:1010-9.
18. Petrie JG, Ohmit SE, Cheng CK, et al. Influenza vaccine effectiveness against antigenically drifted influenza higher than expected in hospitalized adults: 2014-2015. Clin Infect Dis 2016; 63:1017-25.
19. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. Available at: http://www. who. int/influenza/vaccines/virus/recommendations/ 201502-recommendation. pdf?ua=1. Accessed 16 November 2016.
20. Couzens L, Gao J, Westgeest K, et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 2014; 210:7-14.
21. Grohskopf LA, Shay DK, Shimabukuro TT, et al. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-2014. MMWR Recomm Rep 2013; 62:1-43.
22. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distribution. J Am Stat Assoc 1989; 84:1065-73.
23. Skowronski DM, Chambers C, Sabaiduc S, et al. A perfect storm: impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season. Clin Infect Dis 2016; 63:21-32.
24. Valenciano M, Kissling E, Reuss A, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Euro Surveill 2016; 21:30139.
25. Monto AS, Petrie JG, Cross RT, et al. Antibody to influenza virus neuraminidase: An independent correlate of protection. J Infect Dis 2015; 212:1191-9.
26. Air GM. Influenza neuraminidase. Influenza Other Respir Viruses 2012; 6:245-56.
27. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011; 204:1879-85.
28. Monto AS, Maassab HF. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 1981; 13:54-7.
29. Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, Hensley SE. Antibodies against the current influenza A(H1N1) vaccine strain do not protect some individuals from infection with contemporary circulating influenza a(H1N1) virus strains. J Infect Dis 2016; 214:1947-51.
30. Zimmerman RK, Nowalk MP, Chung J, et al. 2014-2015 influenza vaccine effectiveness in the United States by vaccine type. Clin Infect Dis 2016; 63:1564-73.
31. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. J Infect Dis 2015; 212:1914-22.
32. Belshe RB, Edwards KM, Vesikari T, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-96.
33. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2016-17 Influenza Season. MMWR Recomm Rep 2016; 65:1-54.